Source: Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar



Rating:

Share or cite this content

Citations should be made in the following way:
V. Cottin (Lyon, France). Prognostic evaluation in connective tissue disease: a pragmatic algorithm. Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar

Member's Comments

No comment yet.

Related content which might interest you: Evaluation and treatment of interstitial lung involvement in connective tissue diseases: a clinical update Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-39-1, page=27 Year: 2005 Case-based imaging of connective tissue disease-related lung disease Source: Virtual Congress 2021 – Imaging grand round Year: 2021 Biomarkers for fibrotic lung disease - new clinical benchmarks from the lab? Source: Annual Congress 2013 –ME3 Biomarkers for fibrotic lung disease – new clinical benchmarks from the lab? Year: 2013 Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help? Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 Diagnostic and prognostic value of an undifferentiated connective tissue disease index in idiopathic interstitial pneumonia Source: Annual Congress 2009 - From genetics to clinics in diffuse parenchymal lung diseases Year: 2009 Demonstration of diagnostic and prognostic benefits of an interstitial lung disease (ILD) multidisciplinary team meeting Source: Annual Congress 2011 - Clinical approach of diffuse parenchymal lung disease Year: 2011 Prognostic validation of cryobiopsy for the diagnosis of interstitial lung diseases Source: International Congress 2019 – Transbronchial cryobiopsy and endobronchial ultrasound Year: 2019 A pragmatic clinical classification for interstitial lung disease Source: Annual Congress 2012 - Reclassification of idiopathic interstitial pneumonias Year: 2012 What if my lung-dominant connective tissue disease (LD-CTD) patient eventually met criteria for a definite CTD: The role of prognosis! Source: International Congress 2015 – Connective tissue disorders Year: 2015 Disease patterns in connective tissue disease-associated interstitial lung disease: a population based study Source: International Congress 2019 – Towards a better understanding of rare diffuse parenchymal lung diseases Year: 2019 Prognostic assessment in chronic obstructive pulmonary disease using copeptin: A simplified risk index Source: International Congress 2015 – Monitoring and phenotyping COPD Year: 2015 Clinical analysis of lung manifestation in Sjögren's syndrome Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Pulmonary manifestations in rheumatoid arthritis: A hospital based descriptive study Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Choosing pharmacotherapy for ILD in patients with connective tissue disease Source: Breathe, 17 (4) 210114; 10.1183/20734735.0114-2021 Year: 2021 CF-ABLE-UK score: Modification and validation of a clinical prediction rule for prognosis in cystic fibrosis on data from UK CF registry Source: International Congress 2015 – Cystic fibrosis: physiology, biomarkers, microbiology and miscellaneous Year: 2015 Significance of connective tissue disease in a typical UK diffuse parenchymal lung disease clinic Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Prognostic evaluation of idiopathic interstitial pneumonia: emerging data Source: Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar Year: 2010 Lung involvement and clinical characteristics in anti-MDA5 positive connective tissue diseases Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: risk stratification and management Year: 2018 Late Breaking Abstract - Prognostic value of serum biomarkers in patients with idiopathic pulmonary fibrosis and correlation with disease progression. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021